Investing.com - Aquestive Therapeutics (NASDAQ: AQST) reported first quarter EPS of $0.110, $0.25 better than the analyst estimate of $-0.140. Revenue for the quarter came in at $11.13M versus the consensus estimate of $9.88M.
Guidance
Aquestive Therapeutics sees FY 2023 revenue of $42.000M-$46.000M versus the analyst consensus of $39.060M.
Aquestive Therapeutics's stock price closed at $1.390. It is up 58.130% in the last 3 months and up 1.460% in the last 12 months.
Aquestive Therapeutics saw 2 positive EPS revisions and 0 negative EPS revisions in the last 90 days. See Aquestive Therapeutics's stock price’s past reactions to earnings here.
According to InvestingPro, Aquestive Therapeutics's Financial Health score is "fair performance".
Check out Aquestive Therapeutics's recent earnings performance, and Aquestive Therapeutics's financials here.
Stay up-to-date on all of the upcoming earnings reports by visiting Investing.com's earnings calendar